{"id":"NCT01662310","sponsor":"Janssen Research & Development, LLC","briefTitle":"An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia","officialTitle":"Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2012-08-10","resultsPosted":"2014-06-06","lastUpdate":"2014-09-29"},"enrollment":201,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Paliperidone","otherNames":["R076477"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Paliperidone: Run-in or Stabilization phase","type":"EXPERIMENTAL"},{"label":"Paliperidone: Double blind (DB) phase","type":"EXPERIMENTAL"},{"label":"Placebo: DB phase","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, tolerability and safety of paliperidone extended release (ER) tablets (between 3 to 12 milligram (mg), once a day) in the prevention of relapse in schizophrenia participants.","primaryOutcome":{"measure":"Double Blind (DB) Phase: Median Time to Relapse","timeFrame":"DB Baseline (Day 1 of Week 15) up to interim analysis data cut-off (24 August 2012) (Approximately 1 year)","effectByArm":[{"arm":"Paliperidone: Double Blind (DB) Phase","deltaMin":null,"sd":null},{"arm":"Placebo: DB Phase","deltaMin":49,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":14,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":201},"commonTop":["Akathisia","Insomnia","Tremor","Constipation","Nasopharyngitis"]}}